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Abstract
Objective: While the majority of current diabetes treatments focus on reducing blood glucose levels, hypoglycemia
represents a significant risk associated with insulin treatment. Glucagon plays a major regulatory role in controlling
hypoglycemia in vivo, but its short half-life and hyperglycemic effects prevent its therapeutic use for non-acute applications.
The goal of this study was to identify a modified form of glucagon suitable for prophylactic treatment of hypoglycemia
without increasing baseline blood glucose levels.
Methodology/Principal Findings: Through application of the XTEN technology, we report the construction of a glucagon
fusion protein with an extended exposure profile (Gcg-XTEN). The in vivo half-life of the construct was tuned to support
nightly dosing through design and testing in cynomolgus monkeys. Efficacy of the construct was assessed in beagle dogs
using an insulin challenge to induce hypoglycemia. Dose ranging of Gcg-XTEN in fasted beagle dogs demonstrated that the
compound was biologically active with a pharmacodynamic profile consistent with the designed half-life. Prophylactic
administration of 0.6 nmol/kg Gcg-XTEN to dogs conferred resistance to a hypoglycemic challenge at 6 hours post-dose
without affecting baseline blood glucose levels. Consistent with the designed pharmacokinetic profile, hypoglycemia
resistance was not observed at 12 hours post-dose. Importantly, the solubility and stability of the glucagon peptide were
also significantly improved by fusion to XTEN.
Conclusions/Significance: The data show that Gcg-XTEN is effective in preventing hypoglycemia without the associated
hyperglycemia expected for unmodified glucagon. While the plasma clearance of this Gcg-XTEN has been optimized for
overnight dosing, specifically for the treatment of nocturnal hypoglycemia, constructs with significantly longer exposure
profiles are feasible. Such constructs may have multiple applications such as allowing for more aggressive insulin treatment
regimens, treating hypoglycemia due to insulin-secreting tumors, providing synergistic efficacy in combination therapies
with long-acting GLP1 analogs, and as an appetite suppressant for treatment of obesity. The improved physical properties
of the Gcg-XTEN molecule may also allow for novel delivery systems not currently possible with native glucagon.
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Introduction
Current diabetes treatment paradigms encourage aggressive
insulin regimens to manage blood glucose levels within normal
ranges and prevent increases in HbA1c [1]. Several studies have
shown that patient outcomes would be further improved by even
more aggressive insulin dosing, but hypoglycemic episodes
represent a limiting adverse effect [2,3,4,5]. While current
treatment methods focus almost exclusively on reducing blood
glucose levels, normal glucose homeostasis requires the action of
multiple hormones with complementary activities in order to
maintain blood glucose in a relatively constant range [6,7].
Therefore, it is likely that treatment with multiple regulatory
hormones may provide a better overall patient outcome by
stabilizing blood glucose within a normal range. Such an approach
may help to reduce the incidence of adverse effects such as
hypoglycemia.
In particular, nocturnal hypoglycemia represents a significant
unmet medical need. Whereas hypoglycemic events during the day
can be recognized and treated with relative ease, nocturnal events
are more problematic. At least one study has shown that the
normal waking response to hypoglycemia is impaired in diabetic
patients [8]. Further, up to 22% of all autopsied deaths among
Australian type I diabetics under 40 years old over a 12 year
period were attributed to complications of nocturnal hypoglycemia
[9]. The therapeutic need is most acute among juvenile type I
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episodes is especially high [10,11,12,13].
The only currently approved drug for treatment of hypoglyce-
mia is glucagon. Glucagon is a key hormone in glucose
homeostasis and normally limits the severity of hypoglycemic
events [14,15]. However, due to its extremely short half-life (,10
minutes), the currently marketed form of glucagon is only
indicated for acute hypoglycemic episodes [16]. Due to the
difficulties associated with detecting nocturnal hypoglycemia, a
long-lasting prophylactic form of glucagon would be preferred.
Recent studies have demonstrated success in preventing nocturnal
hypoglycemia using continuous infusion and slow-release depot
formulations of very low dose glucagon [17]. However, these
approaches are limited due to the physical properties of the
glucagon peptide itself. Glucagon is highly insoluble and unstable
in liquid formulations [16], limiting its application in pumps or
other continuous administration strategies.
XTEN technology may represent an opportunity to optimize
the glucagon peptide for prophylactic applications. The XTEN
sequence has been demonstrated to controllably increase the
serum half-life of peptides and proteins [18]. In addition, fusion of
the XTEN sequence can increase the solubility and stability of the
attached peptide, while simultaneously enabling recombinant
production and improved manufacturing. The XTEN sequence
has been shown to be safe and poorly immunogenic in a number
of animal species. We therefore constructed a series of glucagon-
XTEN fusion constructs (Gcg-XTEN) to assess the in vivo effects of
extended glucagon exposure.
We chose to focus initially on identifying a Gcg-XTEN capable
of preventing nocturnal hypoglycemia. For this indication, a
specific pharmacodynamic profile is required. An ideal molecule
should maintain efficacious serum levels for approximately
8–10 hours after administration to cover the patient’s sleeping
period. However, to reduce possible interactions with normal
insulin usage in the patient during the day, the ideal construct
would fall below efficacious serum levels between 10 and 12 hours
after administration. An additional concern regarding long-term
glucagon administration is the potential for an overall increase in
serum glucose levels, which could lead to a worsening of the
patient’s disease state. Thus, a critical feature of the final molecule
is a flat exposure profile that maintains an efficacious dose while
minimizing effects on baseline glucose levels. Demonstration of
efficacy without significant increase in blood glucose may also
enable development of XTEN fusions capable of preventing
hypoglycemia at weekly to monthly dosing intervals. Long-term
resistance to hypoglycemia would allow for more aggressive insulin
regimens for patients, providing improved patient outcomes while
reducing the incidence of adverse effects.
Results
XTEN Optimization
In order to determine the ideal Gcg-XTEN for overnight
administration, four length variants were constructed. These
constructs comprised the mammalian glucagon peptide sequence
with either 288, 144, 72, or 36 amino acids of XTEN sequence
genetically fused to the C-terminus (Fig 1A). The four fusions
covered a broad range of hydrodynamic radii, dependent on the
length of the XTEN sequence attached, consistent with the
expected bulking effects of the XTEN sequence (Fig 1B).
The constructs were injected subcutaneously into cynomolgus
monkeys in order to determine their pharmacokinetic profiles
(Fig 1C). The observed terminal half lives correlated with the
length of the attached XTEN sequence. Construct 1, comprising
288 amino acids of XTEN sequence, demonstrated the longest
exposure profile with a terminal half-life of approximately 9 hrs.
For treatment of nocturnal hypoglycemia, however, the target
exposure profile is a constant serum concentration over the first
8–10 hours followed by rapid clearance, as described above.
Construct 2, comprising 144 amino acids of XTEN sequence, best
approximates the desired profile and hence this XTEN length was
chosen for further study.
While blood glucose measurements were taken at multiple
timepoints after administration in the PK studies, high interanimal
variability and intraanimal fluctuations prevented the observation
of PD effects that could be directly correlated with the observed
PK. However, potential pharmacodynamic effects of construct 1
were observed in fasted cynomolgus monkeys (Fig 2). Fasted
animals were administered either 7 nmol/kg construct 1 or
placebo. Food was made available ad libitum at six hours after
dosing. Placebo treated animals showed an immediate increase in
serum glucose levels, consistent with an eating response. In
contrast, when the same animals were treated with construct 1, no
increase in serum glucose after return of food was noted. This
effect is consistent with suppression of appetite, which is a known
biological effect of glucagon [19]. These observations suggest that
construct 1 is biologically active in cynomolgus monkeys with
effects that last for at least 6 hours, significantly longer than would
be expected for unmodified glucagon.
To address concerns regarding potential elevations of blood
glucose levels after chronic administration of long-lived glucagon
constructs, construct 1 was administered to diet-induced obese
mice for 28 days. Due to the more rapid clearance of XTEN
proteins in small rodents than in larger species [18], the protein
was administered twice per day to ensure sufficient exposure of the
animals over the course of the study. Consistent with the potential
appetite suppression effects observed in the monkeys above,
continuous administration of construct 1 resulted in a significant
reduction in weight gain relative to placebo treated animals (Fig 3).
This effect has potential applications for treatment of a number of
disease indications. Importantly, no significant change in fasting
blood glucose was observed after chronic dosing of construct 1
(Fig 4), suggesting that pharmacologically active doses that do not
increase baseline blood glucose may be possible in larger animals
as well.
Construction and Biophysical Characterization of
Gcg-XTEN
The XTEN sequence in construct 2 was replaced with a
different sequence of identical length in order to reduce the overall
charge of the molecule, thereby improving its purification
properties with regard to separation from DNA and other
process-related impurities (data not shown). Based on data for
multiple XTEN sequences and payloads [18], no difference in the
PK profile of construct 2 is expected due to the change in the
XTEN sequence composition. This molecule is referred to as Gcg-
XTEN. Gcg-XTEN was expressed in Escherichia coli and purified to
homogeneity (Fig 5; see Methods). The purified protein was found
to have 15% of the potency (on a molar basis) of unmodified
glucagon in in vitro cell-based assays (Fig 5B). This activity level was
found to be constant over constructs 1–4 as well (data not shown),
suggesting that the apparent reduction in potency may result from
steric hindrance at the C-terminus of the glucagon peptide.
In order to test the solubility and liquid stability of Gcg-XTEN,
the protein was concentrated to 3.6 mM (58 mg/mL) in Tris-
buffered saline at neutral pH. It is important to note that no visible
aggregates or significant viscosity was noted at this stage; therefore
this value should be considered a lower limit of potential solubility
Gcg-XTEN
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glucagon in the same buffer was measured at 0.06 mM (0.2 mg/
mL), demonstrating that the XTEN sequence confers an increase
in solubility of at least 60-fold. Characterization of the Gcg-XTEN
solution by reverse-phase HPLC and size exclusion chromatogra-
phy indicates that the protein is homogeneous and non-aggregated
in solution (Fig 5C,D). Further, the protein was found to be stable
in liquid formulation for at least 6 months under refrigerated
conditions (Fig 5D,E) and for approximately one month at 37uC
(data not shown). Formulation optimization and excipient
screening using standard methods have not yet been attempted,
and may allow for even longer stability in liquid formulations.
In vivo Characterization
The pharmacodynamics of Gcg-XTEN were evaluated in
fasted dogs. In order to demonstrate the functionality and
Figure 1. Optimizing the pharmacokinetic profile of Gcg-XTEN. (A) Schematic representations of four glucagon constructs. The length of
attached XTEN in number of amino acids is indicated on each construct. (B) Size exclusion chromatography of the four purified constructs.
Chromatograms are labeled and colored for each construct as in panel A. The dashed chromatogram shows the profile of a mixed reference size
standard (BioRad Laboratories). The molecular weight of each reference peak is noted. A large increase in apparent molecular weight due to an
increased hydrodynamic radius is typically observed for XTEN fusion proteins in this assay. (C) Pharmacokinetic profile of constructs 1–2 over
24 hours in cynomolgus monkeys. Curves are labeled and colored as in panel A. For construct 2, serum concentration at 24 hours was below limit of
detection (approximately 0.1 nM), hence the dashed line approximates the slowest terminal half-life consistent with this observation. Construct 3 was
also tested in parallel, but was below limit of detection at all time points, suggesting that it has a very short plasma half-life. Based on the rapid
clearance of construct 3, construct 4 was not tested in animals.
doi:10.1371/journal.pone.0010175.g001
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XTEN was administered at relatively high dose (12 nmol/kg)
where an increase in blood glucose levels was expected. Gcg-
XTEN administration was found to rapidly increase blood
glucose levels in the dog model (Fig 6). While administration of
unmodified glucagon resulted in a return to baseline blood
glucose levels within 2 hours (Fig 6A), animals treated with Gcg-
XTEN showed elevated blood glucose levels for 10–12 hours
following subcutaneous injection (Fig 6B). The increase in blood
glucose levels due to Gcg-XTEN was found to be dose
dependent, with doses 0.6 nmol/kg or lower showing no
significant increase in blood glucose (Fig 6C). This is consistent
with the results of the study of construct 1 in diet-induced obese
mice, where 28 days continuous dosing of 0.7 nmol/kg yielded a
slight decrease in fasting blood glucose levels relative to placebo
treatment (Fig 4). To minimize potential elevation of baseline
blood glucose levels, the 0.6 nmol/kg dose was selected for
further study.
Figure 2. Construct 1 inhibits increase in blood glucose after end of fasting in cynomolgus monkeys. The effect of long-lived construct 1
on appetite suppression was tested in normal cynomolgus monkeys. Panels A–C show overlaid plots of blood glucose profiles after placebo or
construct 1 administration for each individual animal. Solid arrows mark the time when food was returned to the animals (t=6 hours).
doi:10.1371/journal.pone.0010175.g002
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hypoglycemia, the molecule was evaluated in an insulin-induced
hypoglycemia model in dogs (Fig 7). To mimic hypothetical
human usage (dosing after dinner, immediately prior to sleep),
animals were fed 3 hours prior to dosing, then fasted for the
remainder of the study. Animals were dosed subcutaneously with
either placebo or 0.6 nmol/kg Gcg-XTEN. To demonstrate
efficacy during the expected ‘sleep’ cycle, insulin was administered
to induce hypoglycemia 6 hours after dosing (Fig 7A). In a
separate experiment, insulin was administered to the same animals
12 hours after dosing to demonstrate that Gcg-XTEN efficacy
does not persist into the expected ‘wake’ cycle (Fig 7B). Gcg-
XTEN-treated animals showed a strong resistance to the
hypoglycemic challenge at 6 hours after dosing, but no resistance
to a challenge 12 hours after dosing. Importantly, no significant
difference in the blood glucose of Gcg-XTEN treated animals
relative to placebo treatment was observed at any point except
during the hypoglycemic challenge at 6 hours. While the fact that
this experiment was conducted in normal dogs allows for the
possibility that increased insulin secretion due to glucose counter-
regulation may have suppressed baseline blood glucose in Gcg-
XTEN treated animals, no significant differences in insulin levels
were noted during the study (Table 1). Further, the results of
chronic dosing in diet-induced obese mice reported above are
consistent with this observation. Thus Gcg-XTEN may prove
useful for the prevention of nocturnal hypoglycemia without
elevating baseline blood glucose.
Discussion
The data presented above show that Gcg-XTEN is effective
at preventing hypoglycemia according to the specifications
outlined for nocturnal hypoglycemia. In particular, the
pharmacodynamic profile has been tuned such that an insulin
challenge at 6 hours after dosing is resisted whereas a challenge
at 12 hours is unaffected. This timing can be mapped onto a
hypothetical timeline of a patient’s usage where Gcg-XTEN
was administered immediately prior to sleep at 21:00. The
insulin challenge at 6 hours post-dose would therefore
Figure 3. Chronic dosing of Construct 1 in Diet-Induced Obese Mice: Weight Loss. Change in body weight in Diet-Induced Obese mice
over the course of 28 days continuous drug administration. Values shown are the average +/2 SEM of 10 animals per group. Groups were found to
be significantly different (p,0.05) by repeated measures ANOVA.
doi:10.1371/journal.pone.0010175.g003
Figure 4. Chronic dosing of Construct 1 in Diet-Induced Obese
Mice: Fasting Blood Glucose. Change in fasting blood glucose in
Diet-Induced Obese mice after 28 days continuous drug administration.
Values shown are the average +/2 SEM of 10 animals per group.
Groups were not found to be significantly different by t test.
doi:10.1371/journal.pone.0010175.g004
Gcg-XTEN
PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10175correspond to 03:00 (Fig 7C) which represents a natural nadir
in blood glucose levels [20]. The insulin challenge at 12 hours
post-dose would similarly correspond to 09:00 on the same
hypothetical timeline. At this time, most patients would have
awakened, eaten a meal, and had their first insulin injection.
The observed lack of effect of Gcg-XTEN on insulin challenge
at this time is therefore significant, suggesting that no residual
activity remains that might interfere with the patient’s normal
daily insulin regimen.
It is important to note that the dogs used in this study had
normal glycemic control and hence may be able to achieve
euglycemia in the presence of low levels of glucagon activity via
insulin counter-regulation. Although no significant differences in
insulin levels were noted in the study, it is possible that the residual
activity threshold for blood glucose elevation may be significantly
higher in this model than in diabetic animals. In addition,
sustained efficacy over multiple doses has not yet been demon-
strated. Further, long-term studies in glycemic clamped animal
models and preclinical models of diabetes are warranted to better
define the potential therapeutic window between hypoglycemia
resistance and hyperglycemia. These data will be important in
designing clinical studies in type 1 diabetes patients to provide the
desired duration of pharmacodynamic effect without increases in
blood glucose.
Figure 5. Biophysical Characterization and Stability of Gcg-XTEN. Gcg-XTEN was produced recombinantly in E. coli and purified to
homogeneity using three column steps (see methods). (A) SDS-PAGE analysis of the purified protein product (lane 2). Molecular weight markers are
shown in lane 1 with relevant size markers labeled at the left. Note that the true molecular weight of the molecule is 16305 daltons (confirmed by
mass spectrometry; not shown). Slow migration in SDS-PAGE relative to globular protein standards is typical of XTEN fusion proteins due to
differences in primary amino acid composition. (B) Glucagon receptor (GcgR) Ca
2+-flux assay comparing the efficacy of Gcg-XTEN to unmodified
glucagon. Calculated EC50 values for each curve fit are shown. (C) Reverse phase C18 HPLC analysis and (D) Size exclusion chromatography HPLC
analysis of the purified Gcg-XTEN construct at the time of production. (E) Reverse phase C18 HPLC analysis and (F) Size exclusion chromatography
HPLC analysis of Gcg-XTEN after 6 months storage at either 280uC (black), 2–8uC (blue), or 25uC (red). Note the scale is expanded in panel E to better
illustrate the appearance of minor peaks at 25uC.
doi:10.1371/journal.pone.0010175.g005
Gcg-XTEN
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hypoglycemia resistance, a large number of other hormones and
signaling peptides have short half-lives and may also be amenable
to optimization by XTEN addition. The recombinant nature of
XTEN fusion proteins allows for rapid screening of variant
constructs, allowing optimization of the pharmacokinetic and
pharmacodynamic profiles for each payload molecule specific to
its desired clinical indication. Thus, we expect that XTEN may
enable new applications for a wide range of novel metabolic
products.
The XTEN sequence confers several additional improvements
to its payload peptide beyond extended pharmacokinetics.
Addition of the XTEN sequence allows the fusion protein to be
expressed recombinantly in E. coli at high yield. This is expected to
result in significant reduction in the manufacturing costs of XTEN
fusions relative to synthetic peptides. Further, the addition of
XTEN can improve the solubility of its payload, in the case of
glucagon by at least 60-fold. Our data also show that Gcg-XTEN
is stable in liquid formulation for extended periods, with no sign of
aggregation typically observed for hydrophobic peptides. These
observations suggest that Gcg-XTEN constructs will be amenable
to real-time monitoring and pump approaches. Such methods are
difficult to implement with the unmodified peptide, due to the
need for a lyophilized formulation. Although in vitro cell-based data
imply that XTEN can reduce biological activity, the Gcg-XTEN
in vivo data show comparable or better glucose mobilization on a
molar dose basis relative to unmodified glucagon (Fig 3C). This
discrepancy is likely due to the increased exposure of Gcg-XTEN
Figure 7. Gcg-XTEN confers temporally-controlled resistance to insulin-induced hypoglycemia in dogs. Beagle dogs were fed three
hours prior to the start of the experiment and fasted thereafter. At time=0, animals received either a dose of 0.6 nmol/kg Gcg-XTEN or placebo (open
arrows). Animals (n=4 per group) received a challenge of 0.05 U/kg insulin to induce hypoglycemia at either 6 hr (A) or 12 hr (B) after initial dose,
indicated by solid arrows. Values shown are the average blood glucose plus or minus the standard deviation. (C) A hypothetical timeline for human
administration. Assuming Gcg-XTEN dosing at 21:00, 6 hr post dose corresponds to 03:00 (during sleep) where protection of hypoglycemia is desired,
and 12 hr post dose corresponds to 09:00 where the pharmacodynamic effect should have expired to allow for a morning meal.
doi:10.1371/journal.pone.0010175.g007
Figure 6. Gcg-XTEN shows extended pharmacodynamics in dogs. Glucagon (A) or Gcg-XTEN (B) was injected at 14 or 12 nmol/kg, respectively, into
fasted beagle dogs (n=4 per group) and blood glucose levels were monitored in comparison to placebo injection. (C) The difference in blood glucose area
under the curve for the first hour after injection of placebo, Gcg-XTEN, or Glucagon (Gcg) relative to pre-injection baseline is shown (n=4–8 animals per group).
The dose level for each group is indicated. Values for all panels are the average values plus or minus the standard deviation.
doi:10.1371/journal.pone.0010175.g006
Gcg-XTEN
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strongly affect overall efficacy of a fusion construct. For payloads
where peak dose toxicity is a concern, lower specific activity of the
XTEN fusion may help to reduce the occurrence of adverse drug
effects.
In addition to the above effects, a significant feature of the Gcg-
XTEN molecule is the achievement of efficacy without an
associated increase in blood glucose levels. While this result
appears initially paradoxical, glucagon is a key signaling hormone
component in the glucose counterregulatory system [14]. Similar
counter-intuitive synergistic effects have been observed with a
molecule capable of agonizing the glucagon and GLP-1 receptors
simultaneously [21]. Sustained Gcg-XTEN levels may therefore
impact a variety of signaling pathways that modulate insulin
sensitivity (among other factors) leading to the observed effects.
The ability to modulate the pharmacokinetic and pharmacody-
namic profiles of glucagon through addition of various XTEN
constructs provides a unique opportunity to characterize this
poorly studied aspect of normal glucose metabolism and
regulation.
While further work will be required to elucidate the precise
mechanism at play, the observed efficacy without increasing
baseline blood glucose levels may be highly significant in enabling
novel therapies. By increasing the size of the attached XTEN
sequence, achievement of up to monthly dosing intervals in
humans is expected [18]. Therefore, it may be possible to create
an XTEN fusion capable of conferring long-term resistance to
hypoglycemia in diabetic patients without increasing long-term
blood glucose levels. Such a construct could also be combined with
long-acting exenatide constructs such as exenatide-LAR [22] or
VRS-859 [18] to better characterize the recently reported synergy
between these two payload activities. Finally, a long-acting
molecule capable of preventing low blood glucose levels (and
associated hunger) without significant adverse effects may
represent an ideal treatment for obesity in otherwise healthy
individuals.
Materials and Methods
Gcg-XTEN Construction
Gcg-XTEN gene construction was performed essentially as
described in ref [18]. The final construct comprised the gene
encoding the cellulosome anchoring protein cohesion region
cellulose binding domain (CBD) from Clostridium thermocellum
(accession #ABN54273), a tobacco etch virus (TEV) protease
recognition site (ENLYFQ), the glucagon sequence, and the
appropriate XTEN sequence under control of a T7 promoter. The
protein was expressed and purified essentially as described for E-
XTEN in ref [18]. Briefly, protein expression was induced by
addition of 1 mM IPTG to a log phase culture of BL21-Gold
(DE3) E. coli carrying the expression plasmid. TEV protease was
added to heat-treated cell lysate containing Gcg-XTEN to remove
the CBD sequence and generate the native N-terminus of
glucagon. The cleaved protein was then purified over DE52,
MacroCap Q, and Butyl Sepharose FF columns. The final
material was formulated in 20 mM Tris pH 7.5, 135 mM NaCl
and sterile filtered using a 0.22 micron filter. Expression was
determined to be approximately 7 mg protein per gram wet cell
weight (,100 mg/L at final OD ,4) and overall purification yield
was approximately 60%.
Animal Welfare Statement
Animal welfare for the studies described herein were performed
in compliance with the U.S. Department of Agriculture’s (USDA)
Animal Welfare Act (9 CFR Parts 1, 2 and 3). The Guide for the
Care and Use of Laboratory Animals, Institute of Laboratory
Animal Resources, National Academy Press, Washington, D.C.,
1996, was followed in all cases. Testing facilities maintain an
Animal Welfare Assurance statement with the National Institutes
of Health, Office of Laboratory Animal Welfare. In order to
ensure compliance, protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) before the initiation of
treatment. No procedures or test articles were used which would
cause more than momentary pain or distress to the animals.
Detailed protocols, in-life summaries, and study reports are on file
at Amunix, Inc.
Blood glucose effects after fasting in cynomolgus
monkeys
The effect of long-lived construct 1 on appetite suppression was
tested in normal cynomolgus monkeys. Animals were fasted for
12 hours prior to dosing and 6 hours following dosing. At time 0,
animals received a randomized dose of either 7 nmol/kg of
construct 1 or placebo. Blood glucose was measured by hand-held
glucometer at designated times throughout the study. In a second
phase, the same animals were treated with the alternate test article
according to the same protocol.
Chronic Dosing in Diet-Induced Obese Mice
The effects of chronic dosing of construct 1 were tested in male
C57BL/6J Diet-Induced Obese (DIO) Mice, age 10 weeks old.
Mice raised on a 60% high fat diet were randomized into
treatment groups (n=10 per group) of construct 1 (0.7 nmol/kg IP
BID) or placebo (20 mM Tris pH 7.5, 135 mM NaCl). Groups
were dosed continuously for 28 days. Body weight was monitored
continuously throughout the study and fasting blood glucose was
measured before and after the treatment period.
Size Exclusion Chromatography
Size exclusion chromatography (SEC) was performed using a
TSK-Gel, G3000 SWXL, 7.86300 mm HPLC column (Tosoh
Bioscience) connected to an HPLC system equipped with an
autosampler and UV/VIS detector (Shimadzu). The system was
equilibrated in phosphate buffered saline (PBS) at a flow rate of
0.7 mL/min at ambient temperature. For column calibration, a
gel filtration standard (BioRad, cat#151-1901) was used. For
sample analysis, 20 ul of 1 mg/ml Gcg-XTEN was injected and
absorbance was monitored for 20 min using OD214nm.
Reverse-Phase Chromatography
Reverse phase C18 chromatography (RPC18) was performed
using a Phenomenex Gemini 5 mm C18, 100 A ˚, 4.66100 mm
column (Phenomenex) connected to an HPLC system equipped
with an autosampler and UV/VIS detector (Shimadzu). Buffer A
was 0.1% TFA in water and Buffer B was 0.1% TFA in 100%
Table 1. Insulin Levels in Gcg-XTEN or placebo treated dogs.
Serum Insulin Concentration
a
Hours post dose 7 13
Gcg-XTEN 5649 62
Placebo 10631 1 64
aConcentration values are reported as mIU/mL 6 standard deviation.
doi:10.1371/journal.pone.0010175.t001
Gcg-XTEN
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1 ml/min. The column was equilibrated in 5% Buffer B at 35uC.
The chromatographic separation of Gcg-XTEN was achieved by a
linear gradient from 5% to 95% B over 15 minutes. For sample
analysis, 10 ml of 1 mg/ml Gcg-XTEN was injected and
absorbance was monitored using OD214nm.
In vitro Bioactivity
Samples analysis was performed by Millipore’s GPCRProfilerH
service using a transfected GcgR cell line (Cat# HTS112C).
Calcium flux was monitored in real-time by FLIPR analysis after
addition of serial dilutions of Gcg-XTEN or synthetic glucagon.
Pharmacokinetics
Pharmacokinetic analysis was performed by administration of
length constructs to individual cynomolgus monkeys at MPI
Research, Inc. (Mattawan, MI). Each compound was dosed
subcutaneously at 12 nmol/kg. Plasma concentrations were
measured using a sandwich ELISA assay. Briefly, 100 ng of rabbit
polyclonal anti-XTEN was immobilized in each well of a
polystyrene microtiter plate (Costar 3690, Corning Inc, Corning,
N.Y.), followed by blocking with 3% bovine serum albumin (BSA).
After 3 washes with PBS, plasma samples were serially titrated
across the plate in PBS containing 1% BSA and 0.5% Tween 20.
After a 2 hour incubation and washing, the samples were probed
by the addition of biotinylated rabbit polyclonal anti-XTEN to
each well. After incubation and washing, plates were developed by
incubation with horseradish peroxidase-conjugated streptavidin
(Thermo Fisher Scientific, Rockford, IL) followed by tetramethyl-
benzidine substrate (Neogen Corporation, Lexington, KY), then
quenched with 0.2 N H2SO4 and read at 450 nm.
Pharmacodynamics
Beagle dogs (four per group) were injected subcutaneously with
designated doses of synthetic glucagon (American Peptide,
Sunnyvale, CA), Gcg-XTEN, or placebo. Animals were fasted
for 12 hours preceding dosing and 6 hours following dosing. Blood
glucose was tested at designated times before and after dosing
using a hand-held glucometer (Walgreens TRUEresult
TM). Raw
data was corrected for systematic bias between human and canine
blood by comparison to reference samples across the entire linear
range (40–250 mg/dL) measured in parallel at a diagnostic
laboratory (Antech Diagnostics).
Hypoglycemic Challenge
Beagle dogs (four per group, eight total) were subjected to a
hypoglycemic challenge model in two phases, separated by a four
day washout period. In each phase, the animals were fed three
hours prior to injection, then fasted for the remainder of the study.
In each phase, groups were injected subcutaneously with 0.6
nmol/kg of Gcg-XTEN or placebo at time zero. In the first phase,
hypoglycemic challenge was initiated 6 hours after test article
injection by administration of 0.05 U/kg insulin (Novolin-R, Novo
Nordisk Pharmaceuticals, Inc.). Hypoglycemic challenge in phase
2 was initiated identically, with the exception of being 12 hours
following test article injection. Blood glucose levels were tested at
designated times using a hand-held glucometer as above. Blood
samples were taken pre-dose and one hour following insulin
challenge in all animals. Samples were tested by clinical chemistry
to confirm accuracy of the hand-held glucometer readings. In
addition, clinical chemistry confirmed significantly elevated insulin
levels following hypoglycemic challenge in all groups. Although
slightly lower (Table 1) in Gcg-XTEN groups relative to placebo
groups, the differences between groups were not statistically
significant at either tested timepoint.
Sequences
Construct 1. HSQGTFTSDYSKYLDSRRAQDFVQWLMNTGG-
EGSGEGSEGEGSEGSGEGEGSEGSGEGEGGSEGSEGEGGSEGS-
EGEGGSEGSEGEGSGEGSEGEGGSEGSEGEGSGEGSEGEGSEG-
GSEGEGGSEGSEGEGSGEGSEGEGGEGGSEGEGSEGSGEGEGS-
GEGSEGEGSEGSGEGEGSGEGSEGEGSEGSGEGEGSEGSGEGE-
GGSEGSEGEGSEGSGEGEGGEGSGEGEGSGEGSEGEGGGEGSE-
GEGSGEGGEGEGSEGGSEGEGGSEGGEGEGSEGSGEGEGSEGG-
SEGEGSEGGSEGEGSEGSGEGEGSEGSGEG
Construct 2. HSQGTFTSDYSKYLDSRRAQDFVQWLMNTGG-
EGGSEGSEGEGSEGSGEGEGGSEGSEGEGSEGSGEGEGGSEGS-
EGEGGSEGSEGEGGEGSGEGEGSEGSGEGEGSGEGSEGEGGSE-
GGEGEGSEGGSEGEGSEGGSEGEGGEGSGEGEGGGEGSEGEGS-
EGSGEGEGSGEGSEG
Construct 3. HSQGTFTSDYSKYLDSRRAQDFVQWLMNTGG-
EGSGEGSEGEGSEGSGEGEGSEGSGEGEGGSEGSEGEGGSEGS-
EGEGSEGGSEGEGGSEGSEGEGSEGGGEG
Construct 4. HSQGTFTSDYSKYLDSRRAQDFVQWLMNTGG-
EGSGEGSEGEGSEGSGEGEGSEGGSEGEGGSEGSEG
Gcg-XTEN. HSQGTFTSDYSKYLDSRRAQDFVQWLMNTGG-
TSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAE-
SPGPGSTSESPSGTAPGSTSSTAESPGPGTSPSGESSTAPGTS-
TPESGSASPGSTSSTAESPGPGTSPSGESSTAPGTSPSGESST-
APGTSPSGESSTAPG
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